ACHE and Alzheimer disease: The evaluation of the clinical effects of tacrine has shown efficacy in delaying the deterioration of the symptoms of AD, but the poor selectivity of this drug for AChE has resulted in a number of side effects, specially hepatotoxicity [3], and current research is focused on developing new AChE inhibitors with improved activity and reduced adverse side effects, therefore novel tacrine analogues have been reported [4,5,6,7,8,9,10,11,12,13,14,15,16,17,18].